BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 10601771)

  • 1. [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group].
    Sainz R; Borda F; Domínguez E; Gisbert JP
    Rev Esp Enferm Dig; 1999 Nov; 91(11):777-84. PubMed ID: 10601771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].
    Buzás GM; Józan J
    Orv Hetil; 2004 Oct; 145(40):2035-41. PubMed ID: 15559530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
    Avidan B; Melzer E; Keller N; Bar-Meir S
    Isr Med Assoc J; 2001 Mar; 3(3):163-5. PubMed ID: 11303370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
    Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
    Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
    Güliter S; Keleş H; Ozkurt ZN; Cengiz DU; Kolukisa E
    Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The attitude of primary health care physicians in the metropolitan area of Barcelona about the diagnosis and treatment of Helicobacter pylori infection in gastroduodenal diseases].
    Martínez-Sánchez G; Saperas E; Benavent J; Mearin F; Piñol JL; Barenys M; Mascort JJ; Forné M; Bordas JM; Azagra R; Piqué JM
    Gastroenterol Hepatol; 1998 Dec; 21(10):473-8. PubMed ID: 9927791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
    Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
    Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines in the medical treatment of Helicobacter pylori infection.
    Dzieniszewski J; Jarosz M
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():143-54. PubMed ID: 17033112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
    Liu CC; Lee CL; Chan CC; Tu TC; Liao CC; Wu CH; Chen TK
    Arch Intern Med; 2003 Sep; 163(17):2020-4. PubMed ID: 14504114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duodenal ulcer healing rates in a one-year follow-up study with ranitidine bismuth citrate and antibiotics.
    Wurzer H; Bardhan KD; Marcelino M; Jahnsen J; Allmaier M
    Hepatogastroenterology; 2001; 48(42):1641-7. PubMed ID: 11813591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the 13c-urea breath test for the initial diagnosis of helicobacter pylori infection and to confirm eradication after treatment.
    Gisbert JP; Ducons J; Gomollón F; Domínguez-Muñoz JE; Borda F; Miño G; Jiménez I; Vázquez MA; Santolaria S; Gallego S; Iglesias J; Pastor G; Hervás A; Pajares JM
    Rev Esp Enferm Dig; 2003 Feb; 95(2):121-6, 115-20. PubMed ID: 12760719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of ranitidine bismuth citrate based triple therapy for treating Helicobacter pylori.
    Thong-Ngam D; Tangkijvanich P; Treeprasertsuk S; Wisedopas N; Kullavanijaya P
    J Med Assoc Thai; 2002 Oct; 85(10):1054-9. PubMed ID: 12501895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
    Buzás György M; Székely E; Illyés G; Széles I
    Orv Hetil; 2000 Jul; 141(31):1711-4. PubMed ID: 10976194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranitidine bismuth citrate-based triple therapy for seven days, with or without further anti-secretory therapy, is highly effective in patients with duodenal ulcer and Helicobacter pylori infection.
    Marchi S; Costa F; Bellini M; Belcari C; Mumolo MG; Tornar A; Spisni R; Torelli E; Maltinti G
    Eur J Gastroenterol Hepatol; 2001 May; 13(5):547-50. PubMed ID: 11396535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative study of the eradication of Helicobacter pylori: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days].
    Bujanda L; Sánchez A; Iriondo C; Santos A; Cosme A; Muñoz C
    An Med Interna; 2001 Jul; 18(7):361-3. PubMed ID: 11534420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment of Helicobacter pylori infection.
    Bytzer P; Dahlerup JF; Eriksen JR; Jarbøl DE; Rosenstock S; Wildt S;
    Dan Med Bull; 2011 Apr; 58(4):C4271. PubMed ID: 21466771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding.
    Peitz U; Leodolter A; Wex T; Schütze D; Wolle K; Welte T; Günther T; Schmidt U; Malfertheiner P
    Z Gastroenterol; 2004 Feb; 42(2):141-6. PubMed ID: 14963786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
    Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
    Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori].
    Grebenev AL; Miagkova LP; Golochevskaia VS; Lapina TL; Sklianskaia OA
    Klin Med (Mosk); 1995; 73(2):34-7. PubMed ID: 7609414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.